Deutsche Bank on Tuesday downgraded British gene and cell therapy company Oxford Biomedica (OXB.L) to hold from buy and reduced its price target to 5.95 pounds sterling from 8 pounds.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)